ProQR Therapeutics Says It Achieved Successful Defense of New Challenge To Its Axiomer IP Portfolio
ProQR Therapeutics Says It Achieved Successful Defense of New Challenge To Its Axiomer IP Portfolio
The company announced it has again successfully defended against opposition filed against a key patent for its ADAR-mediated RNA editing platform Axiomer.
該公司宣佈，它再次成功抗辯了針對其ADAR介導的RNA編輯平台Axiomer的一項關鍵專利提出的異議。
The opposition was filed in June 2021 with the European Patent Office (EPO) by a strawman against ProQR's granted patent EP 3 507 366 B1, which relates to editing oligonucleotides that have certain chemical modifications in the base and/or ribose sugar to increase stability and recruit endogenous ADAR to edit the target adenosine. This patent is part of ProQR's intellectual property estate surrounding its Axiomer RNA editing platform and the current generation of its molecules. The Opposition Division of the EPO held a public hearing on April 17, 2024, and ruled such that ProQR's strong IP position on chemically modified editing oligonucleotides was maintained.
2021年6月，一位草人向歐洲專利局（EPO）提出異議，反對ProQR的授權專利EP 3 507 366 B1，該專利涉及編輯在鹼基和/或核糖中具有某些化學修飾的寡核苷酸以提高穩定性，並招募內源性ADAR來編輯目標腺苷。該專利是ProQR圍繞其Axiomer RNA編輯平台及其最新一代分子的知識產權的一部分。歐洲專利局反對部於2024年4月17日舉行了公開聽證會，裁定ProQR在化學改性寡核苷酸編輯方面的強大知識產權地位得以維持。
The patent contains broad platform claims including: "An antisense oligonucleotide (AON) capable of forming a double stranded complex with a target RNA sequence in a cell, preferably a human cell, for the deamination of a target adenosine in the target RNA sequence by an ADAR enzyme present in the cell...", which protects ProQR's proprietary ADAR mediated RNA editing platform Axiomer.
該專利包含廣泛的平台主張，包括：“一種反義寡核苷酸（AON）能夠在細胞（最好是人體細胞）中形成具有靶RNA序列的雙鏈複合物，用於通過細胞中存在的ADAR酶對目標RNA序列中的靶腺苷進行脫氨化...“，它保護了ProQR專有的ADAR介導的RNA編輯平台Axiomer。
"This decision further supports the confidence we have in the broad scope conferred by our IP estate protecting our proprietary Axiomer ADAR-mediated RNA editing technology platform, and the use of chemically modified oligonucleotides to increase stability and recruit endogenous ADAR to edit the target adenosine," said René Beukema, Chief Corporate Development Officer and General Counsel. "Given the importance and value of our IP portfolio, we intend to continue to defend against such challenges and remain confident in our leading position, as we progress our science, platform, and pipeline."
首席企業發展官兼總法律顧問雷內·博克瑪表示：“這一決定進一步支持了我們對保護我們專有的Axiomer ADAR介導的RNA編輯技術平台的知識產權所賦予的廣泛範圍的信心，以及使用經過化學改性的寡核苷酸來提高穩定性並招募內源性ADAR來編輯靶腺苷。”“鑑於我們知識產權組合的重要性和價值，我們打算繼續抵禦此類挑戰，並對我們的領先地位保持信心，以推動我們的科學、平台和研發進程。”
ProQR invented the use of endogenous ADAR in RNA editing in 2014 and filed a first patent application in that same year.
ProQR於2014年發明了在RNA編輯中使用內源性ADAR，並於同年提交了第一份專利申請。
譯文內容由第三人軟體翻譯。